FEATURED CONTENT

• Busting Through Patient Recruitment Barriers

  Building patient trust fuels engagement, data and technology enable targeted recruitment, and real-time patient identification with consistent support drives scalable enrollment success.

• Clinical Trial Starts Rose At Slower Pace In 2024

  Clinical trial starts grew 5.5% to 10,503 in 2024, a slowdown from 2023’s 9.4% rise in trial starts. Sustained geopolitical and global regulatory pressures on pharma contributed to curbing momentum.

• Drilling Down On Diversity And Feasibility

  A mid-sized contract research organization (CRO) sought help with writing clinical trial diversity action plans and assessing feasibility for therapeutic areas outside its usual scope.

• Retention Begins With Recruiting The Right-Fit Patients

  Recruiting the right patients into a clinical trial is only half the battle. To combat attrition, sponsors must also institute measures that ensure patients remain comfortable and confident throughout the trial.

• 4 New Approvals In Q3 Across Gene, Cell, RNA Therapies

  Q3 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals. While regulatory progress continued, clinical development activity slowed.

• The Complexities Of Effective Patient Retention In Clinical Trials

  Identifying and enrolling the right-fit patients from the outset is essential, but so is implementing comprehensive retention strategies that prioritize patient comfort, trust, and ongoing engagement.

• What Is ICH GCP, And How Does It Impact Clinical Planning?

  The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.

• Clinical Trial Disclosure Noncompliance: What Is Its Impact On Pharma M&As?

  Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.

• Challenges, Opportunities For Recruitment In The Digital Age

  Health literacy gaps and online misinformation hinder clinical trial recruitment. Meeting patients where they are — digitally and educationally — can improve engagement and enrollment success.

• The Healing Power Of Support Groups

  Support groups offer emotional strength and connection for patients and caregivers, helping them navigate medical challenges, treatment journeys, and the complexities of chronic conditions.

• How AI Is Reshaping Trial Design, Execution, And Disclosure

  AI has quietly embedded itself into the operational heart of clinical development, where it is accelerating decisions, reducing manual burden, and improving outcomes.

• A New Blueprint For Transforming Feasibility And Recruitment

  Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.

• Real-World Data Has Real Impact On Clinical Research

  The ultimate goal of using real-world data (RWD) in clinical research is to ensure a patient is on the right therapy and receiving the right care at the right point in their healthcare journey.

• AI Won't Replace You — But Clinical Teams Using It Might

  Join experts as they reveal how AI is being used today across feasibility, site selection, and trial strategy — and why success depends on pairing AI with high-quality, expert-backed data.

• Infographic: Every Completed Trial, Every Emerging Trend

  Explore the data behind every trial completed last year — uncovering key trends, leading sponsors, and therapeutic areas shaping the future of clinical research.

• Biotech Landscape Continues To Shift

  Global shifts are adding new layers of challenge and opportunity for the biotech sector, as companies navigate a period of unprecedented complexity.

• Expand Bandwidth With A Trusted Regulatory Writing Partner

  Find out how a mid-size biotech lacking the bandwidth, expertise, and resources to independently handle its regulatory writing requirements overcame this challenge.

• ICH E6(R3): 10 FAQ On What Changed And What It Means For Your Trials

  The ICH E6(R3) updated guidelines present 10 critical changes to make clinical trials more efficient, adaptable, and patient-centric, while upholding the standards of scientific and ethical integrity.

• Inclusive Trial Design A 'Must-Have' In Modern R&D

  Inclusivity in trial design is a crucial aspect of the R&D process, recognized for its importance to ensuring scientific validity, ethical responsibility, and public health.

• Gene Therapy Studies Rose While Financing Declined In Q2 2025

  There were three new approvals across the therapeutic landscape in the second quarter of 2025, but despite those positive signs, overall dealmaking was flat for the quarter.